Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowLilly (LLY) announced the acquisition of Centessa Pharmaceuticals, focusing on OX2R drug candidates for sleep disorders. This strategic move aims to enhance LLY's portfolio in the sleep medicine market, which has seen increasing demand. Financial terms of the deal were not disclosed, but the acquisition is anticipated to bolster LLY's research and development capabilities. The market impact could reflect positively on LLY's stock as they expand their therapeutic offerings.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Stocks Soar on Hopes of Iran War Resolution Amid Market Optimism
- Centessa (CNTA) Downgraded After Lilly Deal Announcement
- Eli Lilly (LLY) acquires Centessa for up to $7.8 billion
- Eli Lilly and Insilico Partner on AI Drug Development Deal Valued at $2.75B
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
